Fisetin as a Senolytic Therapy

Evidence Review created on 08/09/2026 using AI4L / Opus 5

Also known as: 3,3’,4’,7-tetrahydroxyflavone, 5-deoxyquercetin, Cognisetin, Novusetin

Motivation

Fisetin is a plant pigment found in small amounts in strawberries, apples, persimmons, and onions. It drew attention in aging research when laboratory screens ranked it the strongest of a group of related plant compounds at killing worn-out cells — cells that have stopped dividing but refuse to die and instead leak inflammatory signals into surrounding tissue. Clearing those cells is one of the more concrete ideas to come out of modern aging biology.

The compound itself is not new. It was extracted from the wood of the smoke bush in the nineteenth century and used as a yellow textile dye long before anyone studied it in a laboratory. Its current reputation rests largely on animal work, where short bursts of high doses given late in life reduced signs of cellular wear. Supplement sales followed quickly, at amounts far above anything food can supply.

This review examines what is known about taking fisetin to clear worn-out cells: how it is thought to work, what human studies have and have not shown, the doses and schedules in use, the safety signals reported so far, and where the evidence runs out.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Fisetin

The article covers fisetin’s chemistry as a flavonol (a subclass of plant polyphenol pigments), its natural sources, and its senolytic literature in one continuous reference entry, and is useful mainly for orienting quickly on nomenclature and plant origins before reading the primary trial literature.

Examine

No Examine article on fisetin exists. Examine does not currently cover fisetin as a supplement, and the compound does not appear anywhere in its supplement database or article index.

ConsumerLab

Can fisetin, also called Cognisetin and Novusetin, really improve memory or slow aging?

This is the only independent consumer-facing review that addresses fisetin product pricing, dosing with or without food, and a reported blood-pressure-lowering effect in a member taking antihypertensive medication. Most of the detail sits behind a paid subscription, and ConsumerLab’s revenue comes from subscriptions rather than from supplement sales.

Systematic Reviews

Systematic reviews of fisetin published on PubMed, selected for relevance to the compound itself, recency, and breadth of the underlying evidence base.

The effects of fisetin on bone and cartilage: A systematic review - Yamaura et al., 2022

Pools 13 preclinical studies of fisetin in bone and cartilage, including osteoarthritis and osteoporosis models, and finds consistent reductions in cartilage breakdown and bone loss driven largely by suppression of inflammatory signalling. Every included study is a cell or animal experiment, so it establishes biological plausibility for the musculoskeletal trials now underway rather than any human effect.
The Neuroprotective Role of Fisetin in Different Neurological Diseases: a Systematic Review - Jiang et al., 2023

Collects fisetin studies across stroke, Alzheimer’s disease, Parkinson’s disease, spinal cord injury, and depression models, and identifies suppression of oxidative stress and of inflammatory signalling as the recurring mechanism. It is the best single map of which neurological indications have preclinical support, and it makes clear that human evidence exists for only one of them.
Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury-A systematic review - Prem et al., 2022

Reviews fisetin in models of myocardial ischemia-reperfusion injury (damage caused when blood flow returns to heart muscle after being cut off, which can injure tissue further). It is useful for its unusually explicit treatment of dose-response and timing, and it notes that protection was lost in diabetic animals — an early signal that metabolic state modifies the response.
Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review - Mohajeri et al., 2026

The most recent systematic review, covering fisetin in drug-induced kidney toxicity, acute kidney injury, and nephropathy (chronic kidney disease). It matters here because the kidney handles a large share of flavonoid conjugates, and the review finds protective rather than harmful signals across models at the doses tested.
Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature - Crocetto et al., 2021

Compares fisetin against two structurally similar flavonols in urological cancer models, which is the clearest available answer to whether fisetin’s effects are specific to it or shared across the flavonol class. The review finds substantially overlapping activity, a caution against treating fisetin as uniquely potent outside the narrow senolytic screening assays.

Mechanism of Action

Fisetin is a flavonol — a plant polyphenol pigment — structurally almost identical to quercetin but lacking one hydroxyl group, which is why it is sometimes called 5-deoxyquercetin. Its proposed senolytic action rests on a specific vulnerability of senescent cells rather than on general antioxidant activity.

The senescent-cell survival problem. Cells that suffer irreparable DNA damage can enter senescence: they stop dividing permanently but stay alive and metabolically active, secreting a mixture of inflammatory proteins, growth factors, and tissue-degrading enzymes known as the senescence-associated secretory phenotype (SASP). To survive despite that self-generated inflammatory pressure, senescent cells upregulate anti-apoptotic pathways (molecular brakes on programmed cell death). Those brakes are the drug target.
BCL-2 family inhibition. The best-supported mechanism is interference with the BCL-2 family of survival proteins, particularly BCL-xL, which senescent cells depend on disproportionately. Fisetin behaves in cell assays like a weak, partial version of the selective BCL-xL inhibitors, tipping dependent cells over the apoptotic threshold while leaving dividing cells intact.
PI3K/AKT pathway suppression. Fisetin inhibits signalling through PI3K/AKT (a growth and survival pathway that also props up the BCL-2 brakes), which lowers the anti-apoptotic reserve of senescent cells from a second direction. Work in diabetic aortic tissue has traced fisetin’s senescent-cell clearance specifically to this route.
Cell-type selectivity, and its limits. Fisetin’s senolytic action is not universal. In the original screening work it selectively killed senescent human umbilical vein endothelial cells (blood-vessel lining cells) but was not senolytic in senescent human lung fibroblasts or in fat-cell precursors. This means “fisetin clears senescent cells” is true only of some tissues, a caveat frequently lost in summaries.
Senomorphic rather than senolytic effects. Independent of killing anything, fisetin suppresses NF-κB (a master switch that turns on inflammatory genes) and the NLRP3 inflammasome (a protein complex that triggers release of inflammatory signals), which quiets the SASP without removing the cells producing it. Liposome-encapsulated fisetin work published in 2025 found this senomorphic effect at concentrations where no senolysis occurred, which is a genuine competing explanation for the anti-inflammatory results seen in human trials.
Metabolic and stress-response signalling. Fisetin activates AMPK (an energy sensor that switches cells toward repair when fuel is scarce), inhibits mTOR (a growth sensor that drives cell building and suppresses cellular recycling), activates SIRT1 (a repair-associated regulatory protein), and induces Nrf2 (a master switch that turns on the cell’s own antioxidant defences). These overlap heavily with the effects of many dietary polyphenols and are not specific to senolysis.
Competing account of the dose-response: hormesis. A 2025 integrated analysis argues that fisetin’s protective effects across cell and animal systems — its senolytic action among them — follow a biphasic dose-response: benefit over a modest dose range, with that benefit shrinking or reversing above it. This reading does not dispute that senescent cells are killed; it disputes the assumption that more fisetin does more of it, and it places the very high intermittent doses used in senolytic protocols at risk of sitting past the optimum. Where that optimum lies in people has never been established, and no human study has been designed to locate it.

Key pharmacological properties. Fisetin’s clinical behaviour is dominated by poor absorption.

Bioavailability. Oral bioavailability of unformulated powder is low single-digit percentages; a single 1,000 mg dose of unformulated fisetin produced a peak plasma concentration of about 10 ng/mL in healthy volunteers, while a galactomannan-hydrogel formulation delivering 192 mg of fisetin reached about 238 ng/mL.
Half-life. Reported elimination half-life is short — in the range of two to four hours in animal work, with human plasma levels falling back toward baseline within roughly twelve hours of a single dose.
Metabolism. Clearance is dominated by phase II conjugation in the gut wall and liver: glucuronidation by UGT enzymes (which attach sugar acids to make compounds water-soluble for excretion), sulfation by SULT enzymes (which attach sulfate groups for the same purpose), and O-methylation by catechol-O-methyltransferase (COMT, an enzyme that inactivates catechol-containing molecules) to geraldol, an active metabolite.
Efflux transport. Efflux transporters including P-glycoprotein (a pump that expels foreign molecules from cells back into the gut lumen) further limit systemic exposure.
Tissue distribution. Distribution is broad but shallow; animal work shows modest blood-brain barrier penetration, with liver and kidney seeing the highest concentrations.
Oxidative clearance. Cytochrome P450 oxidation (the CYP enzyme family, the liver’s main drug-metabolising system) plays a secondary role in fisetin’s own clearance but is central to its interaction profile.

Historical Context & Evolution

Original use: a textile dye. Fisetin was isolated in the 1830s from the heartwood of the smoke bush, Cotinus coggygria, and from Toxicodendron succedaneum. Under the name young fustic it was a standard yellow-to-ochre dye for wool and silk until synthetic dyes displaced it late in the nineteenth century. Its chemistry was characterised by Schmidt in 1886 and its structure confirmed by synthesis by Kostanecki in the 1890s. It had no medicinal role.
Twentieth-century reframing as a dietary antioxidant. Through the 1990s and 2000s fisetin was studied as one flavonoid among hundreds, with work on antioxidant capacity, inhibition of lipoxygenase (an enzyme that converts fatty acids into inflammatory signalling molecules), and anticancer activity in cell lines. Pamela Maher’s group at the Salk Institute produced the most sustained line of work, showing neuroprotective and memory-enhancing effects in rodents and arguing that fisetin acted through multiple pathways rather than by scavenging free radicals — a finding that anticipated the later mechanistic literature.
The senolytic turn. In 2015 the Mayo Clinic group led by James Kirkland and Tamara Tchkonia identified dasatinib and quercetin as the first senolytics, on the reasoning that senescent cells depend on identifiable anti-apoptotic pathways. In 2017 the same group reported that fisetin was senolytic in senescent endothelial cells and had lower toxicity than the alternatives. In 2018 a screen of ten flavonoid polyphenols ranked fisetin the most potent senotherapeutic of the set, and reported that intermittent late-life dosing in wild-type mice reduced senescence markers across tissues, reduced age-related pathology, and extended median and maximum lifespan. That single paper is the origin of essentially all subsequent consumer interest.
What the historical findings actually showed. The 2018 lifespan result was obtained in aged inbred mice given fisetin either acutely or intermittently late in life, with senescence markers measured in a mouse strain engineered to age prematurely and to flag worn-out cells, and confirmatory work in human fat tissue kept alive outside the body. The reported gain in median lifespan was on the order of 10 percent, with maximum lifespan also extended. The human tissue arm showed reduced senescence markers in a subset of cells only — the paper itself framed the effect as cell-type-specific, not global.
The replication that did not follow. The United States National Institute on Aging’s Interventions Testing Program subsequently tested fisetin in genetically heterogeneous mice across three independent sites, the design specifically built to filter out strain- and site-specific lifespan results. Fisetin did not significantly affect lifespan in either sex at the doses and schedules used. This has not been characterised in the literature as a refutation of the 2018 work, and there are substantive reasons the two could both be correct: different mouse genetics, continuous dietary dosing rather than intermittent high-dose bursts, different starting ages, and different achieved tissue concentrations. What changed is the confidence a reader can place in lifespan extension as a fisetin effect; what has not changed is the cell and tissue evidence for senolysis, which the lifespan programme did not test.
Commercialisation ahead of evidence. Consumer fisetin products appeared within months of the 2018 publication, and by the early 2020s branded forms (Novusetin, Cognisetin) and bioavailability-enhanced formulations were widely marketed. Human trials began in 2018 at Mayo Clinic and have expanded to more than thirty registered studies, but as of mid-2026 the large majority have not published results, and no completed trial has reported a senescent-cell or clinical outcome for fisetin in older adults. The evidence base and the market have moved on very different timescales.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Circulating Inflammatory Markers

Fisetin lowers blood levels of several inflammatory signalling proteins. This is the fisetin benefit supported by the largest number of randomized controlled trials (RCT — a study in which participants are assigned to treatment or placebo by chance, the strongest design for causal inference). Four placebo-controlled trials in different populations agree in direction: colorectal cancer patients on chemotherapy taking 100 mg daily for seven weeks, acute stroke patients, and two 2026 trials of 200 mg daily for twelve weeks in men with obesity. The proposed mechanism is suppression of NF-κB signalling and of the SASP. The important limitation is that none of these trials measured senescent-cell burden, so the anti-inflammatory effect cannot be attributed specifically to senolysis rather than to the direct anti-inflammatory activity fisetin shares with many flavonoids; the trials are also small (37 to 192 participants, three of the four under 100), short, and conducted in disease states rather than in healthy older adults.

Magnitude: In colorectal cancer patients, interleukin-8 (an inflammatory signalling protein) fell significantly versus placebo, with high-sensitivity C-reactive protein (hs-CRP, a general marker of body-wide inflammation) and matrix metalloproteinase-7 (a tissue-remodelling enzyme) falling significantly within the fisetin group. In men with obesity, fisetin alone significantly reduced interleukin-6 and tumour necrosis factor-alpha, and fisetin combined with training reduced monocyte chemoattractant protein-1 by about 47 percent.

Medium 🟩 🟩

Improved Outcomes When Added to Clot-Dissolving Therapy in Acute Ischemic Stroke

In a double-blind placebo-controlled trial, stroke patients receiving standard clot-dissolving treatment with recombinant tissue plasminogen activator were also given fisetin or placebo, stratified by how long after symptom onset treatment began. Patients treated late did substantially better on stroke severity scoring when fisetin was added, and the benefit tracked with lower serum levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and C-reactive protein — consistent with fisetin protecting the blood-brain barrier from reperfusion injury. This is a single-centre trial that has not been replicated, and it addresses an acute hospital setting rather than the preventive use this review is concerned with, which is why it is graded Medium rather than High.

Magnitude: Stroke severity scores were significantly lower in the fisetin arm among patients with delayed onset-to-treatment time; the authors describe the practical effect as extending the usable treatment window from roughly three hours to roughly five hours.

Improved Glucose, Insulin, and Lipid Measures Alongside Exercise

Two double-blind randomized trials published in 2026 tested 200 mg of fisetin daily for twelve weeks in sedentary men with obesity, alone and combined with interval resistance plus aerobic training. Fisetin alone produced significant weight loss and improvements in fasting glucose, insulin, and insulin resistance versus placebo; combined with training it produced the largest changes in every metabolic measure. The plausible mechanism is AMPK activation and mTOR inhibition, mirroring the animal metabolic literature. Both trials come from the same research group in a single population of men with obesity, none of whom were older adults, so generalisation to the audience for this review is an assumption rather than a finding.

Magnitude: Fasting blood glucose, insulin, and insulin resistance fell significantly in every active arm including fisetin alone; in the training-plus-fisetin arm, low-density lipoprotein cholesterol, triglycerides, and total cholesterol all fell and high-density lipoprotein cholesterol rose significantly, while the placebo group deteriorated on both cholesterol measures.

Low 🟩

Selective Clearance of Senescent Cells in Human Tissue

The founding claim for fisetin as a senolytic rests on cell and tissue work rather than on measurements in living people. In senescent human umbilical vein endothelial cells fisetin selectively triggers apoptosis while sparing dividing cells, and in human fat tissue kept alive outside the body it reduced senescence markers in a subset of cells. Selectivity is real but partial: in the same experiments fisetin was not senolytic in senescent human lung fibroblasts or in fat-cell precursors. No published human study has measured senescent-cell burden before and after fisetin dosing in vivo, which is the single largest gap in the evidence base and the reason this sits at Low despite being the mechanism the entire field is built on.

Magnitude: In a head-to-head screen of ten flavonoid polyphenols in senescent murine and human fibroblasts, fisetin was the most potent senotherapeutic of the set; in human endothelial cells it killed senescent but not proliferating cells, while showing no senolytic activity at all in lung fibroblasts or fat-cell precursors.

Preserved Physical Function and Reduced Frailty

Intermittent fisetin in aged mice improved measures of physical function and reduced senescence markers in skeletal muscle, with a 2025 comparison finding effects broadly in line with genetic clearance of senescent cells and with synthetic senolytics. Reduced frailty and inflammation were also among the endpoints of the original 2018 mouse work. Several human trials with frailty and physical-function endpoints have been running since 2018 in older adults, childhood cancer survivors, and breast cancer survivors, but none has published results, so the human side of this claim is currently empty.

Magnitude: In old mice, intermittent fisetin improved physical function to a degree comparable with genetic elimination of senescent cells; no corresponding human magnitude has been reported.

Joint and Cartilage Protection

Across the 13 preclinical studies pooled in a systematic review, fisetin reduced cartilage degradation and bone loss in osteoarthritis and osteoporosis models, apparently by suppressing inflammatory signalling in joint tissue and shifting bone marrow stromal cells toward bone formation. Senescent cells accumulate in osteoarthritic cartilage, which makes the mechanism coherent. Human trials in knee osteoarthritis and after meniscus repair have used fisetin only inside multi-drug combinations, several were withdrawn or suspended, and none has reported a fisetin-attributable result.

Magnitude: Benefit was reported in all 13 pooled preclinical studies, with reductions in cartilage breakdown markers and preservation of cartilage thickness in every osteoarthritis model tested and reduced bone loss in every osteoporosis model tested; no human joint outcome has been quantified.

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

The 2018 mouse study reported that fisetin given late in life extended median and maximum lifespan by roughly 10 percent, a result that drove essentially all subsequent consumer interest. The United States National Institute on Aging’s Interventions Testing Program then tested fisetin across three independent sites in genetically heterogeneous mice — a design built specifically to expose strain- and site-dependent results — and found no significant lifespan effect in either sex. Neither result has been retracted or explained away. Plausible reasons for the discrepancy include mouse genetic background, continuous dietary dosing in the replication versus intermittent high-dose bursts in the original, differences in starting age, and differences in achieved tissue concentration. No human lifespan data exist and none are in prospect, so for this audience the claim rests entirely on animal evidence that is currently in direct conflict.

Preservation of Blood Vessel Function

In old mice, intermittent fisetin improved arterial function and reduced arterial senescence, with follow-up work in 2026 identifying the SASP factor CXCL12 (a signalling protein released by senescent cells that summons other cells into the tissue) as a partial mediator and further work showing protection against chemotherapy-induced premature vascular aging. Vascular endothelium is one of the cell types in which fisetin is reliably senolytic, so this is among the better-motivated speculative benefits. A placebo-controlled trial in older adults has completed dosing but has not reported results, so at present the basis is mechanistic and animal only.

Neuroprotection and Cognitive Preservation

Fisetin protects neurons and preserves memory across rodent models of Alzheimer’s disease, Parkinson’s disease, stroke, and spinal cord injury, acting through antioxidant, anti-inflammatory, and pro-autophagy routes (autophagy is the cell’s own recycling of damaged internal components) rather than through senolysis specifically. Blood-brain barrier penetration in animals is modest but measurable. There are no controlled human cognitive data: the two published human trials touching this domain used fisetin as an add-on in acute stroke and, in a small placebo-controlled crossover study in veterans with Gulf War Illness (a chronic multi-symptom illness reported by Gulf War veterans), found no reduction in symptom severity at either dose tested — neither addressed cognitive preservation, and a small trial in mild Alzheimer’s disease is only now recruiting. The basis for this benefit is therefore mechanistic and preclinical only.

Chemopreventive and Antitumour Activity

Fisetin suppresses proliferation, induces apoptosis, and blunts invasion and metastasis across a wide range of cancer cell lines and rodent tumour models, acting largely through the same PI3K/AKT and mTOR inhibition and NF-κB suppression that underlie its other effects rather than through senolysis. One of the systematic reviews cited above pools this literature for prostate and bladder cancer, and it finds that fisetin’s activity is substantially shared with the structurally similar flavonols kaempferol and myricetin, which argues against any compound-specific antitumour property. The only human trial to give fisetin alongside cancer treatment measured inflammatory and tissue-remodelling markers in 37 colorectal cancer patients and reported no oncological endpoint at all. The basis for this item is therefore mechanistic and preclinical only, with no controlled human evidence that fisetin prevents, slows, or treats any cancer.

Protection of Kidney Function

Fisetin preserved kidney function and structure across models of drug- and toxin-induced kidney damage, acute kidney injury, and nephropathy arising from diabetes or lupus (kidney disease caused by those conditions), pooled in a 2026 systematic review. The routes are the familiar ones — antioxidant defence, suppression of inflammatory signalling, blocked cell death, and reduced scarring of kidney tissue — rather than senolysis, and the direction of the signal matters for safety as well as benefit, because the kidney clears a large share of fisetin’s conjugates. Every study included was in cells or animals, and no human kidney endpoint has been reported after fisetin, so the basis for this item is mechanistic and preclinical only.

Protection of Liver Function

Fisetin reduced fat accumulation, inflammation, scarring, and cell death in the liver across rodent models of fatty liver disease, chemical and drug-induced liver injury, and fibrosis, and it accelerated liver regeneration after partial removal in one 2026 report. The routes are again the shared ones — suppression of inflammatory signalling, activation of the cell’s own antioxidant defences, and blunted programmed cell death — rather than senolysis, and they overlap with the metabolic effects seen in the human obesity trials. This direction matters for safety as well as benefit, since the liver performs most of fisetin’s conjugation and is the organ a poorly absorbed flavonoid load reaches at the highest concentration. Every study is in cells or animals, no human liver endpoint has been reported after fisetin, and the liver enzymes tracked in the monitoring panel are there as a safety check rather than as an expected benefit, so the basis for this item is mechanistic and preclinical only.

Reduction in Biological-Age Measures ⚠️ Conflicted

Two small uncontrolled studies have pointed in opposite directions. In a six-month pilot in ten healthy adults over 50 taking 500 mg daily for one week per month, four participants showed a reduction in a commercial epigenetic age estimate, five showed an increase, and one was unchanged, with telomere length unchanged; the authors concluded against use for this purpose. In a separate longitudinal study, adding fisetin to dasatinib plus quercetin appeared to blunt the epigenetic age acceleration that the drug pair alone had produced. Neither study had a control group, both had around ten to nineteen participants, and both originate from the same clinician working with a commercial epigenetic-testing company, which has a direct interest in the use of such tests. No controlled evidence supports fisetin lowering any measure of biological age.

Benefit-Modifying Factors

COMT variants: Catechol-O-methyltransferase converts fisetin to geraldol, an active but differently distributed metabolite. The common Val158Met variant produces a roughly three-to-four-fold range in enzyme activity between individuals, which plausibly shifts the ratio of parent compound to metabolite and therefore the tissue distribution of activity. This has not been tested directly with fisetin.
UGT1A and SULT1A1 variants: These enzymes attach sugar acids and sulfate groups to fisetin in the gut wall and liver, and are the main reason oral bioavailability is low. Reduced-function variants of UGT1A1 and the common SULT1A1*2 low-activity allele would be expected to raise systemic exposure from an identical dose, potentially by more than formulation changes achieve.
ABCB1 (P-glycoprotein) variants: ABCB1 encodes an efflux pump that returns absorbed compounds to the gut lumen. Common variants alter pump expression severalfold and are a plausible source of the wide between-person variation in fisetin plasma levels observed in the human pharmacokinetic study.
Baseline senescent-cell burden: This is the most important modifier and the best evidenced. In the phase 2 senolytic bone trial, skeletal benefit appeared only in the top tertile (the highest of three equal-sized groups) of women ranked by T-cell p16 messenger RNA (a marker of senescent-cell burden), with no effect in the group overall. If that pattern generalises, fisetin’s benefit depends on there being enough senescent cells to remove — meaning younger or metabolically healthy users may have little to gain.
Baseline inflammatory markers: Every human trial showing benefit was conducted in populations with elevated inflammation — active cancer, acute stroke, or obesity. In people whose hs-CRP and interleukin-6 are already low, the observed anti-inflammatory effect has less headroom, and the size of any benefit should be expected to shrink accordingly.
Sex-based differences: The 2018 mouse lifespan work and much of the mechanistic literature used both sexes, but the Interventions Testing Program analysis found no lifespan effect in either sex, and sex-divergent responses are the rule rather than the exception for aging-slowing compounds in that programme. Both published metabolic trials enrolled men only; the two longest-running frailty trials enrolled women only or mixed cohorts. There is currently no basis for expecting equivalent effects in men and women, and no basis for expecting different ones either.
Pre-existing health conditions: Diabetes abolished fisetin’s cardioprotection in animal ischemia-reperfusion models, which is a direct warning that metabolic disease may blunt rather than amplify benefit. Conversely, conditions marked by high senescent-cell burden — prior chemotherapy or radiotherapy, chronic kidney disease, obesity, chronic viral infection — are the states in which the mechanism predicts most benefit, and are where most active trials are being run.
Age-related considerations: Senescent-cell burden rises steeply after roughly age 60, so the mechanistic case for benefit strengthens with age, including at the older end of the range. Working against this, absorption of poorly soluble compounds tends to fall with age as gastric acid production and intestinal surface area decline, and a dedicated pharmacokinetic comparison of fisetin in young versus old adults is only now under way. Neither effect has been quantified.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Absence of Long-Term Human Safety Data

The most substantiated risk of fisetin is what is not known about it. Every published human trial has been small and short, and no completed trial has followed participants for long enough to detect a delayed harm. This matters more for fisetin than for a typical supplement, because the intended mechanism is the deliberate elimination of a cell population that also has physiological roles in wound healing, tissue remodelling, and tumour suppression. The evidence basis for this item is the trial registry and publication record itself, which is complete and unambiguous; the practical consequence is that reassuring short-term tolerability data cannot be extrapolated to the years-long intermittent use that consumer protocols imply.

Magnitude: The largest published fisetin trial randomised 192 patients, and every other published trial has enrolled fewer than 100; the longest published continuous dosing period is twelve weeks, and the longest intermittent regimen studied is six monthly cycles. No trial has followed participants beyond about six months after the last dose.

Medium 🟥 🟥

Gastrointestinal Intolerance at Senolytic Doses

The doses used in senolytic protocols are far above dietary exposure — commonly 20 mg per kilogram of body weight per day, or roughly 1,400 mg for a 70 kg adult, taken for two to three consecutive days. Because fisetin is poorly absorbed, most of that dose stays in the gut, where flavonoid loads reliably produce loose stools, nausea, cramping, and bloating. Reports across the fisetin trial programme and consumer sources describe these as the dominant complaints, they are dose-dependent and reversible, and no serious gastrointestinal adverse event has been reported in any published trial. Bioavailability-enhanced formulations reduce the gut load for the same delivered dose and would be expected to reduce this problem.

Magnitude: Mild-to-moderate gastrointestinal complaints are the most frequently reported adverse effect at 20 mg/kg/day; no serious gastrointestinal adverse events and no treatment discontinuations for gastrointestinal reasons have been reported in published trials, including the trial of 500 mg daily for one week per month over six months, in which no adverse effects were noted.

Interference with Drug Metabolism and Transport

Dietary flavonoids as a class inhibit cytochrome P450 enzymes — notably CYP3A4 and CYP2C9, which between them metabolise a large share of prescription drugs, and CYP1A2, which clears caffeine, theophylline, and several psychiatric medications — as well as UGT and SULT conjugation and P-glycoprotein efflux. Fisetin is a substrate for all of these systems and competes for them. The evidence is in vitro and class-level rather than fisetin-specific, and the concentrations used in those assays are generally above what unformulated oral fisetin achieves in plasma. The concern is greatest in the gut wall, where local fisetin concentrations after a senolytic dose are orders of magnitude higher than plasma concentrations and where CYP3A4 and P-glycoprotein do much of their first-pass work.

Magnitude: Flavonoid inhibition of CYP3A4, CYP2C9, UGT, SULT, and P-glycoprotein is documented at micromolar concentrations in vitro; no human drug-interaction study of fisetin has been published, so the clinical magnitude is unquantified.

Low 🟥

Genotoxicity at Supraphysiological Concentrations

Flavonols including fisetin act as topoisomerase II poisons at high concentrations (topoisomerase II is an enzyme that manages DNA unwinding, and the flavonol traps it in a state that leaves DNA strand breaks behind). Work in glioblastoma cells (glioblastoma is an aggressive brain tumour) published in 2024 confirmed genotoxic and cytotoxic activity for fisetin, and this class effect is the mechanism behind long-standing concerns that high-dose flavonoid exposure in pregnancy is associated with a specific infant leukaemia subtype. The concentrations required are far above what oral dosing achieves in plasma, and no genotoxic signal has appeared in any human fisetin study, which is why this is graded Low rather than higher.

Magnitude: Genotoxic effects appear in cell assays at tens of micromolar; peak human plasma concentration after a 1,000 mg unformulated dose is roughly 0.03 micromolar, and roughly 0.8 micromolar with the best-absorbed formulation studied.

Additive Blood-Pressure Lowering

Flavonols have modest vasodilatory and antihypertensive activity, and fisetin has shown blood-pressure-lowering effects in animal models. ConsumerLab has documented a subscriber taking antihypertensive medication who reported several hours of lowered blood pressure after a fisetin dose. This is an isolated report rather than a trial finding, but it is mechanistically plausible and clinically actionable, particularly for people already on multiple blood-pressure-lowering agents or prone to standing-up dizziness (orthostatic hypotension — a drop in blood pressure on standing that causes lightheadedness).

Magnitude: Not quantified in available studies.

Additive Bleeding Risk

Flavonols inhibit platelet aggregation — the clumping of the blood cells that start a clot — in cell and ex vivo work, and fisetin additionally competes for CYP2C9, the enzyme that clears warfarin, so a senolytic dose can add to the effect of anticoagulant and antiplatelet medication already in use. The evidence is class-level and pharmacokinetic rather than fisetin-specific: no bleeding event has been reported in any published fisetin trial, and the trials of the intermittent protocol excluded participants on therapeutic anticoagulation rather than measuring what happened to them. Risk is concentrated in people on warfarin, on dual antiplatelet therapy, or combining high-dose fish oil, ginkgo, garlic, or vitamin E, and in the period around surgery or an invasive procedure. Any effect is expected to be reversible within a day of the last dose given the short half-life, which is the main argument for confining exposure to a small, predictable number of dosing days.

Magnitude: Not quantified in available studies.

Possible Interference with Chemotherapy and Radiotherapy

Fisetin’s antioxidant and anti-apoptotic-pathway effects raise the standard concern that high-dose antioxidant supplementation could blunt treatments that work by generating oxidative damage. The direct evidence points the other way — in colorectal cancer patients fisetin was given alongside chemotherapy without any reported reduction in treatment effect, and preclinical work more often shows fisetin sensitising tumour cells than protecting them. The risk is therefore theoretical and specific to concurrent active cancer treatment, but the trials were small and not powered for oncological outcomes.

Magnitude: In the only trial of fisetin given during chemotherapy, 100 mg daily for seven weeks alongside treatment produced no reported adverse effect on treatment tolerability or outcome in 37 patients; no larger dataset exists.

Speculative 🟨

Impaired Tissue Repair and Wound Healing ⚠️ Conflicted

Senescent cells are not purely pathological. They appear transiently at wound sites, in fracture healing, and in liver fibrosis resolution, where their secretions recruit immune cells and coordinate repair. A drug that removes them indiscriminately could in principle slow healing if taken around surgery, injury, or fracture. Against this, topical fisetin improved rather than impaired wound healing in diabetic mice, and a spatiotemporal analysis of fracture healing suggests the harm would depend entirely on timing relative to injury. There are no controlled human data, so the basis here is mechanistic reasoning and conflicting animal reports only.

Effects of Clearing Senescent Immune Cells

A substantial share of the senescent-cell burden measured in humans sits in T cells, which is why T-cell p16 messenger RNA is used as a biomarker. Removing senescent immune cells might restore immune function, or might deplete a memory compartment in older people whose immune reserve is already narrow. Animal work on senolytics in influenza infection found reduced immune cell infiltration without improved outcomes, which is at least consistent with the second reading. No human immune-function endpoint has been reported after fisetin.

Weak Hormonal Activity

Flavonoids can bind estrogen receptors weakly and can inhibit steroid-metabolising sulfotransferases, and fisetin has shown effects on ovarian and endometrial tissue in cell and animal models. Whether the exposures achieved by oral dosing are anywhere near sufficient to matter is unknown, and no human hormonal endpoint has been measured after fisetin. The basis is mechanistic and from isolated in vitro reports only.

Hypersensitivity to Botanically Sourced Material

Commercial fisetin is extracted from the wood of trees in the sumac family (Anacardiaceae) — the branded material used in the stroke trial was described as wax-tree derived — and several species in that family carry urushiol, the resin responsible for poison-ivy contact rashes. A purified extract should not carry meaningful urushiol, but purity is a supplier specification rather than an independently verified figure, so residual plant allergen in a poorly characterised botanical is a plausible route to hypersensitivity reactions such as rash, itching, or swelling. Every fisetin trial protocol screens out participants with known hypersensitivity or allergy to fisetin, which shows the concern is recognised even though no allergic event has been reported in any published trial. The basis for this item is therefore the botanical origin and trial exclusion criteria rather than reported cases.

Risk-Modifying Factors

CYP2C9 and CYP3A4 variants: These enzymes clear warfarin, many statins, several anticoagulants, and a long list of other drugs. Individuals carrying reduced-function CYP2C9 alleles already clear those drugs slowly; adding a flavonoid that competes for the same enzyme narrows the margin further. This is genotype-modified risk rather than a fisetin-specific finding.
UGT1A1 variants (Gilbert’s syndrome): Reduced UGT1A1 activity, present in roughly 5 to 10 percent of people, slows glucuronidation. It would be expected to raise systemic fisetin exposure and simultaneously to increase competition for a pathway already operating near capacity.
Baseline liver and kidney function: Fisetin conjugates are cleared renally and the parent compound is handled hepatically. Reduced estimated glomerular filtration rate (eGFR — a calculated measure of kidney filtering capacity) or impaired liver function raises exposure to both compound and metabolites. The systematic review evidence in kidney models is protective rather than toxic, but that work used healthy animals.
Baseline blood pressure and antihypertensive load: People already at the low end of normal blood pressure, or on two or more blood-pressure-lowering drugs, carry the additive-hypotension risk described above; those with normal pressure on no medication effectively do not.
Sex-based differences: No sex-stratified safety analysis of fisetin in humans exists. Both published metabolic trials enrolled only men; the earliest frailty trial enrolled only women. Women’s generally lower body weight means weight-based dosing delivers similar exposure, but body composition differences affect distribution of a fat-soluble compound, and no data address this.
Pre-existing health conditions: Active cancer treatment, recent or planned surgery, bleeding disorders or anticoagulant use, and inflammatory bowel disease each intersect with one of the risks above. Diabetes is a specific case: it abolished fisetin’s protective effect in cardiac animal models, so the risk-benefit balance may differ there in ways not yet characterised.
Age-related considerations: Older adults, including those at the upper end of the target range, take a larger number of medications at once, so the drug-interaction risk rises with age even though the exposure risk from a given dose may not. They also have less physiological reserve for the gastrointestinal fluid losses that high flavonoid doses can cause, and are the group most likely to be taking blood-pressure-lowering medication.

Key Interactions & Contraindications

CYP3A4 substrates with narrow safety margins (tacrolimus, cyclosporine, everolimus, sirolimus, simvastatin, lovastatin, some calcium channel blockers): Caution — fisetin taken as a large intermittent gut load may inhibit intestinal CYP3A4 and P-glycoprotein, raising drug levels and the risk of toxicity such as kidney injury with calcineurin inhibitors (transplant anti-rejection drugs that suppress the immune system, here tacrolimus and cyclosporine) or muscle breakdown with statins. Mitigation: separation of fisetin dosing from these drugs by several hours, omission of dosing days entirely where the drug has a narrow therapeutic index, and drug-level testing during the first dosing cycle where levels are routinely monitored.
CYP2C9 substrates, especially warfarin: Caution to absolute contraindication without monitoring — competition for CYP2C9 plus the mild antiplatelet activity common to flavonols can raise anticoagulant effect and bleeding risk. Mitigation: an international normalised ratio (INR — a standardised measure of blood clotting time) check within a week of starting a fisetin cycle and after each subsequent cycle, or no combination at all.
Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) and antiplatelet agents (clopidogrel, ticagrelor, aspirin): Caution — these depend on P-glycoprotein and, for several, CYP3A4, and the clinical consequence of raised exposure is bleeding. Mitigation: no high-dose fisetin cycles in anyone on dual antiplatelet therapy, and discontinuation at least two weeks before any planned procedure.
Antihypertensive medications (angiotensin-converting enzyme inhibitors such as lisinopril, angiotensin receptor blockers such as losartan, calcium channel blockers such as amlodipine, diuretics such as hydrochlorothiazide and furosemide): Monitor — additive blood-pressure lowering has been reported anecdotally and is mechanistically plausible, with the clinical consequence being dizziness or falls in older adults. Mitigation: blood-pressure measurement on the first two days of a dosing cycle, and dosing at a time of day when a transient drop is least hazardous.
Glucose-lowering medications (metformin, sulfonylureas such as glipizide, insulin, SGLT2 inhibitors such as empagliflozin and dapagliflozin — sodium-glucose cotransporter 2 inhibitors, a class of diabetes drugs that increase urinary glucose excretion): Monitor — fisetin lowered fasting glucose and insulin resistance in controlled trials, and additive effects with sulfonylureas or insulin could produce low blood sugar. Mitigation: fasting glucose testing during the first cycle where an agent capable of causing hypoglycaemia is in use.
Over-the-counter medications: Monitor — non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin) add gastrointestinal irritation to a dose that is already a large gut load, and add antiplatelet effect; proton pump inhibitors (omeprazole, esomeprazole) raise gastric pH, which may further reduce dissolution of an already poorly soluble compound; antacids (calcium carbonate, aluminium and magnesium hydroxide) taken at the same time have the same effect; caffeine — in coffee, tea, energy products, and caffeine tablets — competes with fisetin for CYP1A2, so habitual intake clears more slowly on dosing days, with jitteriness, palpitations, or disrupted sleep as the consequence, which is why the Mayo trial protocol asks participants to halve caffeine intake before and during the two dosing days. Mitigation: at least two hours of separation from acid-suppressing agents, a halving of habitual caffeine intake on dosing days, and no overlap between a fisetin cycle and sustained non-steroidal anti-inflammatory drug use.
Supplements with additive senolytic or antiplatelet effects (quercetin, dasatinib in combination protocols, curcumin, high-dose fish oil, ginkgo, garlic extract, vitamin E above 400 international units): Caution — quercetin is fisetin’s closest structural relative and shares its enzyme-inhibition profile, so combining them compounds rather than diversifies the interaction risk; the others add antiplatelet effect. Mitigation: no overlapping quercetin and fisetin protocols, and a pause in high-dose antiplatelet supplements during dosing days.
Supplements with additive blood-pressure-lowering effects (dietary nitrate and beetroot extract, magnesium, hibiscus, coenzyme Q10, aged garlic extract, potassium salts): Monitor — these share fisetin’s vasodilatory direction, and the clinical consequence of combining them on a dosing day is symptomatic hypotension or dizziness, particularly alongside antihypertensive medication. Mitigation: seated and standing blood-pressure readings on the first dosing days of a cycle, and no new blood-pressure-active supplement introduced during a cycle.
Supplements with additive glucose-lowering effects (berberine, chromium picolinate, alpha-lipoic acid, cinnamon extract, high-dose inositol): Monitor — fisetin lowered fasting glucose and insulin resistance in controlled trials, so combining it with these compounds, and especially with insulin or a sulfonylurea, could produce low blood sugar. Mitigation: fasting glucose testing during the first cycle where any glucose-lowering agent or supplement is in use.
Supplements that alter absorption or conjugation (piperine, high-dose vitamin C, calcium and magnesium salts, dietary fibre supplements): Monitor — piperine inhibits glucuronidation and P-glycoprotein and can raise fisetin exposure unpredictably; mineral salts and bulk fibre taken simultaneously reduce absorption of a compound that has little to spare. Mitigation: a co-supplement regimen held constant across cycles so that the dose delivered is at least consistent.
Other interventions (dasatinib, losartan, platelet-rich plasma injection, chemotherapy, immunotherapy): Caution — fisetin is used inside multi-agent protocols alongside dasatinib, losartan, and platelet-rich plasma in orthopaedic trials, and alongside chemotherapy and immunotherapy in oncology trials, and the clinical consequence is that any adverse effect cannot be attributed to a single component. In every published combination the other agents dominate the interaction profile; fisetin’s contribution to combined toxicity has not been isolated in any of them. Mitigation: use of these combinations only inside a trial or under the supervising specialist who prescribed the other agent.
Populations who should avoid this intervention: pregnancy and breastfeeding, without exception, given the topoisomerase II class effect and the absence of any reproductive safety data; anyone with active cancer on treatment, outside a trial and without oncologist agreement; solid organ transplant recipients on calcineurin inhibitors; anyone with a bleeding disorder or on therapeutic anticoagulation without INR monitoring; anyone within two weeks either side of surgery or a planned invasive procedure; people with severe hepatic impairment (Child-Pugh Class B or C — a scoring system for liver disease severity, where Class C is the most advanced) or with an eGFR below 30 mL/min/1.73 m²; people with symptomatic orthostatic hypotension or a history of falls attributable to it; and anyone under 18, for whom no data of any kind exist.

Risk Mitigation Strategies

Full medication and supplement review before the first cycle: A complete list of every prescription drug, over-the-counter medication, and supplement, screened specifically for CYP3A4 and CYP2C9 substrates with narrow safety margins, anticoagulants, and antihypertensives, is the standard first step. This mitigates the drug-metabolism and bleeding risks, which are the only fisetin risks with a plausible route to serious harm.
A reduced dose on the first cycle: Using roughly half the intended dose — for example 500 mg rather than 1,000 to 1,400 mg on day one — establishes gastrointestinal tolerance before committing to a full senolytic load, and mitigates the dose-dependent nausea, cramping, and loose stools that are the most common adverse effect.
Intermittent rather than continuous dosing: Restricting exposure to two or three consecutive days per month, rather than daily use, limits cumulative exposure to enzyme inhibition, genotoxic potential, and interference with tissue repair, while matching the “hit-and-run” logic of the preclinical work. It also confines any drug-interaction window to a small, predictable number of days.
Dosing with a fat-containing meal and adequate fluid: Fisetin is poorly water-soluble; taking it with dietary fat improves dissolution and taking it with 300 to 500 mL of fluid reduces the local gut irritation that drives the gastrointestinal side effects. This also reduces the temptation to escalate dose in response to apparent lack of effect.
Four or more hours of separation from narrow-margin medications: Timing separation reduces peak intestinal co-exposure, which is where the CYP3A4 and P-glycoprotein interaction is strongest. This mitigates raised drug levels for immunosuppressants, statins, and anticoagulants without requiring the medication to be stopped.
Perioperative suspension of dosing: Holding fisetin for two weeks either side of surgery, dental procedures, or injury mitigates both the bleeding risk from additive antiplatelet effect and the theoretical impairment of wound healing from removing senescent cells that participate in repair.
Blood-pressure checks on dosing days of the first two cycles: A seated reading before the dose and two to four hours after it will detect the additive hypotension that has been reported anecdotally, particularly in people on two or more antihypertensive agents, before it causes a fall.
Early clotting-time check on warfarin: An international normalised ratio measurement within seven days of the first cycle mitigates the most consequential interaction — an unrecognised rise in anticoagulant effect — at trivial cost, and establishes whether subsequent cycles need monitoring at all.
A single third-party-tested product held constant across the protocol: Purity and actual fisetin content vary widely across unregulated products, and switching formulations can change delivered exposure by more than twenty-fold. Holding the product constant mitigates unintended dose escalation, which is the mechanism by which most of the risks above would be triggered.

Therapeutic Protocol

The intermittent high-dose protocol (Mayo Clinic): The most widely referenced regimen, derived from the Kirkland and Tchkonia group’s trial designs, is 20 mg per kilogram of body weight per day for two consecutive days, repeated monthly — roughly 1,400 mg daily for two days in a 70 kg adult. The rationale is “hit-and-run” pharmacology: senescent cells need weeks to months to reaccumulate, so continuous exposure is unnecessary and only adds interaction risk. This is the design used in the Mayo frailty trials and in the COVID-19 pilots.
The continuous low-dose protocol: The only human trials showing anti-inflammatory and metabolic benefit used continuous daily dosing at 100 mg (colorectal cancer, seven weeks) or 200 mg (obesity, twelve weeks). These regimens are anti-inflammatory rather than senolytic in intent, are far better tolerated, and are the only fisetin schedules with positive randomized evidence behind them. Presenting the intermittent protocol as the standard obscures the fact that the continuous protocol is the one with human results.
The intermediate protocol: A pilot in adults over 50 used 500 mg daily for one week per month over six months. Its own authors concluded against the approach after biological-age measures moved in both directions, so it is included here for completeness rather than as a supported option.
Where each approach originated: The intermittent senolytic protocol traces to James Kirkland and Tamara Tchkonia at Mayo Clinic, who also hold patents in this area; the continuous anti-inflammatory dosing derives from the Tabriz University trial in colorectal cancer and the University of Kurdistan exercise trials; the monthly week-on schedule originates with the Institute for Hormonal Balance, a private clinic. No independent body has issued a protocol, and no head-to-head comparison of the schedules exists.
Best time of day: No chronobiological data exist for fisetin. Dosing with the largest fat-containing meal of the day is the practical choice for absorption, and morning or midday dosing is preferable to evening on the intermittent protocol, so that any blood-pressure drop or gastrointestinal reaction occurs while awake.
Half-life and its implications: Reported elimination half-life is short — roughly two to four hours in animal work, with human plasma levels approaching baseline within about twelve hours of a single dose. A short half-life is precisely why continuous protocols dose daily and why intermittent protocols concentrate the dose into consecutive days rather than spreading it.
Single versus split dosing: Because absorption is saturable and solubility-limited, splitting a large intermittent dose into two or three portions across the day is likely to deliver more total fisetin than one large single dose and is clearly gentler on the gut. Continuous low-dose protocols used single daily doses and need no splitting.
Genetic considerations for dose choice: COMT, UGT1A1, SULT1A1, and ABCB1 variants each plausibly shift systemic exposure from an identical dose, in some cases by more than a formulation change would. None has been studied with fisetin, so genotype cannot currently guide dosing; it does explain why between-person variation in response should be expected to be large.
Sex-based differences in dosing: Weight-based dosing is used in all senolytic protocols, which partly compensates for body-size differences. No trial has reported sex-stratified pharmacokinetics or efficacy, and the two positive metabolic trials enrolled men only, so any assumption of equivalent dosing in women is an extrapolation.
Age-related considerations: Senescent-cell burden and therefore mechanistic rationale rise with age, while absorption of poorly soluble compounds tends to fall. A dedicated pharmacokinetic comparison in young versus old adults is only now under way. For adults at the older end of the range, the practical implications are to favour a bioavailability-enhanced formulation over raw powder and to weight the interaction review more heavily, given the larger number of medications typically taken at that age.
Baseline biomarkers influencing response: The strongest available predictor of senolytic response in humans is baseline senescent-cell burden, measured as T-cell p16 messenger RNA, which was the only variable separating responders from non-responders in the phase 2 bone trial. That assay is not clinically available. Baseline hs-CRP and interleukin-6 are available and, on the trial evidence, mark the population in which the anti-inflammatory effect has room to appear.
Pre-existing conditions influencing response: Diabetes abolished fisetin’s protection in cardiac animal models, and the disease populations in which human benefit has been shown — active cancer, acute stroke, obesity — are all high-inflammation states. Response in a metabolically healthy adult with low inflammatory markers should be expected to be smaller than any published trial suggests.

Discontinuation & Cycling

Lifelong versus short-term use: Fisetin was never designed for continuous lifelong use, and the mechanism does not require it. The senolytic logic is explicitly intermittent — clear a cell population, then wait months for it to reaccumulate — which makes fisetin closer to a periodic intervention than to a daily supplement. The continuous protocols that have positive human data ran for seven and twelve weeks and were not open-ended.
Withdrawal effects: None have been reported in any published trial or case report. Fisetin has no receptor-dependence mechanism, no tolerance phenomenon has been described, and its short half-life means it clears within a day of the last dose. Stopping produces no known physiological rebound.
Tapering: Not applicable. There is no pharmacological basis for tapering a compound with a two-to-four-hour half-life and no withdrawal syndrome, and no protocol in the literature includes one.
Cycling for efficacy: Cycling is the intended design rather than a strategy to preserve efficacy. Monthly two-to-three-day pulses, or one-week-per-month schedules, are the published patterns. There is no evidence that continuous use loses effect over time, and equally no evidence that it does not — the question has never been tested in people.
Reasons to stop: Persistent gastrointestinal symptoms beyond the dosing days, any unexplained bruising or bleeding, symptomatic light-headedness on standing, a planned procedure within two weeks, initiation of any narrow-margin medication, or simply the absence of any measurable change in the biomarkers being tracked after three or four cycles. The last is the most common and least acted upon.

Sourcing and Quality

Purity and assay: Supplement-grade fisetin is typically extracted from the wood of the smoke bush, Cotinus coggygria, or of the wax tree, Toxicodendron succedaneum, and marketed at 98 percent purity. That figure is a supplier specification, not an independently verified one. A current certificate of analysis showing assayed fisetin content, and testing for residual solvents, heavy metals, and microbial contamination, is the minimum reasonable check for a wood-extracted botanical.
Third-party testing: Fisetin is not covered by Examine and has not been the subject of a ConsumerLab comparative product test, so there is no independent head-to-head purity ranking of fisetin products. In its absence, the available quality signals are testing by an accredited independent laboratory with lot-specific results, and participation in a recognised independent supplement certification programme such as NSF Certified for Sport or United States Pharmacopeia verification, which very few fisetin products currently carry.
Formulation matters more than dose: The single largest source of variation between products is not label dose but absorption. A galactomannan-hydrogel formulation delivering 192 mg of fisetin produced roughly twenty-seven times the plasma exposure of 1,000 mg of unformulated powder in a crossover study in healthy volunteers. Liposomal, phytosomal, and cyclodextrin-complexed forms make similar claims with weaker or no human data. That study was funded by the formulation manufacturer and co-authored by employees of a supplement retailer, which is the only human bioavailability comparison that exists.
Reputable sources: Established supplement manufacturers with published testing programmes — Life Extension, Doctor’s Best, Swanson, Toniiq, and Renue by Science among those most commonly stocked — sell fisetin; note that Life Extension both sells fisetin and publishes the widely cited consumer literature on it. Compounding pharmacies do not generally prepare fisetin, since it is a dietary supplement rather than a prescription item, so this is a retail rather than a pharmacy decision.
Branded versus generic material: Novusetin and Cognisetin are branded fisetin ingredients with defined specifications; branding provides traceability to a specific manufacturing process but does not by itself indicate superior absorption. Unbranded bulk fisetin powder is substantially cheaper and is what most intermittent high-dose protocols actually use, given the gram-scale quantities involved.
Storage and stability: Fisetin is a polyphenol and oxidises on exposure to light, heat, and humidity, which degrades it to inactive products without any visible change. Storage in the original opaque, sealed container away from heat, and avoidance of bulk powder decanted into transparent containers, preserves potency across the months that an intermittent protocol implies.

Practical Considerations

Time to effect: For the anti-inflammatory endpoint, the human trials measured change after seven to twelve weeks of continuous dosing, so several weeks is the realistic timeframe for a measurable shift in inflammatory markers. For the senolytic endpoint there is no human time-to-effect data at all, because no human study has measured senescent-cell burden after fisetin; the animal work implies days for clearance and weeks to months for reaccumulation, but that is an inference from a different species.
Common pitfalls: Taking raw powder and assuming label dose equals delivered dose is the most consequential error, given the twenty-seven-fold spread between formulations. Others: combining fisetin with quercetin on the assumption they are complementary when they are near-identical structurally and compete for the same clearance pathways; running intermittent protocols indefinitely without ever measuring anything; expecting an intervention validated in high-inflammation disease states to produce comparable changes in a metabolically healthy adult; and treating the 2018 mouse lifespan figure as an established property of the compound when a larger, independent replication found nothing.
Regulatory status: In the United States fisetin is sold as a dietary supplement under the Dietary Supplement Health and Education Act, meaning it requires no pre-market approval for safety or efficacy and no claim of disease treatment may lawfully be made. It is not an approved drug in any jurisdiction, and no regulator has evaluated it for senolytic use. All clinical use is investigational, and every senolytic protocol described in consumer literature is an off-label extrapolation from trial designs rather than an approved regimen.
Cost and accessibility: Fisetin is inexpensive and freely available without prescription — unformulated powder runs to a few tens of US dollars per month even at gram-scale intermittent dosing, and branded capsules typically 20 to 50 US dollars per month. Bioavailability-enhanced formulations cost several times more. Cheapness has a second-order consequence worth naming: fisetin is unpatentable as a natural product, so no manufacturer has a commercial reason to fund the large, long trials that would settle its value, and no insurer or national health system will ever be asked to pay for it. The same asymmetry works in the opposite direction for patented senolytics in development, where sponsors have strong incentive to fund trials — meaning the comparative evidence base is likely to remain lopsided in favour of the expensive options regardless of which compound works better.

Interaction with Foundational Habits

Sleep: Interaction appears to be none to weakly indirect. Fisetin has no stimulant or sedative activity, no reported effect on sleep architecture in any trial, and no plausible receptor mechanism for one. A 2025 trial is testing fisetin with urolithin A on sleep and aging biomarkers, so a direct effect has not been excluded, but nothing currently supports one. The practical consideration runs the other way: evening dosing on intermittent high-dose days risks nocturnal gastrointestinal disturbance, so morning or midday dosing is preferable.
Nutrition: Interaction is direct and potentiating in one respect, blunting in another. Fisetin is fat-soluble and poorly water-soluble, so taking it with a fat-containing meal meaningfully improves dissolution and absorption — this is the single easiest lever on delivered dose. Conversely, simultaneous calcium or magnesium salts, bulk fibre supplements, and acid-suppressing medication reduce absorption. Dietary fisetin from strawberries (about 160 micrograms per gram, by far the richest common source), apples, persimmons, and onions is nutritionally worthwhile but is two to three orders of magnitude below supplemental doses and cannot substitute for them. No nutrient depletion by fisetin has been reported.
Exercise: Interaction is direct and potentiating, and this is the best-evidenced foundational-habit interaction fisetin has. In both 2026 randomized trials, fisetin combined with twelve weeks of interval resistance plus aerobic training produced larger improvements in inflammatory markers, insulin resistance, body weight, and lipids than either alone, and the combination arm was the only one to improve every lipid measure. Fisetin alone also produced significant effects, so the relationship is additive rather than dependent. There is no evidence that fisetin blunts training adaptation the way high-dose vitamin C and E supplementation can, though the antioxidant-blunting question has not been directly tested for fisetin; timing doses away from the immediate post-workout window is a low-cost hedge.
Stress management: Interaction is indirect. Fisetin has no reported effect on cortisol or on the hypothalamic-pituitary-adrenal axis (the brain-to-adrenal hormone circuit that governs cortisol release) in humans, and no anti-anxiety or stress-resilience claim has been tested. The indirect link runs through inflammation: chronic psychological stress raises the same inflammatory signals fisetin lowers, and it also accelerates cellular senescence, so stress management and fisetin plausibly act on a shared endpoint from opposite ends. Practically, that means stress load is a confounder when interpreting any inflammatory marker used to judge whether fisetin is working.

Monitoring Protocol & Defining Success

Before starting, a baseline panel serves two purposes: it establishes whether there is any inflammatory or metabolic signal for fisetin to move, and it captures the safety parameters most likely to shift. The core baseline set is a complete blood count (CBC — a measure of red cells, white cells, and platelets), a comprehensive metabolic panel (CMP — electrolytes, kidney measures, and the liver enzymes alanine aminotransferase and aspartate aminotransferase, abbreviated ALT and AST, which leak into the blood when liver cells are stressed), high-sensitivity C-reactive protein, interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) where available, fasting glucose and insulin, a lipid panel, blood pressure measured seated and standing, and — for anyone on warfarin — an international normalised ratio. Baseline testing is done within four weeks before the first dose, while medication and supplement use is stable.

Ongoing monitoring is timed to the protocol rather than the calendar. On a continuous low-dose regimen, inflammatory and metabolic markers are repeated at 8 and 12 weeks, then every 6 months. On an intermittent regimen, blood pressure is checked on dosing days of the first two cycles, liver and kidney measures are repeated after cycle 3, and the full inflammatory and metabolic panel is repeated after cycle 6 — roughly 6 months — then every 6 to 12 months thereafter. Any change in prescription medication resets this schedule.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
High-sensitivity C-reactive protein (hs-CRP)	< 0.5 mg/L	Primary target; the marker most consistently moved by fisetin in trials	Fasting not required but preferred. Invalid within 2–3 weeks of infection, injury, or hard training. Conventional labs call < 3.0 mg/L normal, which is far too permissive to detect change
Interleukin-6 (IL-6)	< 1.5 pg/mL	Upstream driver of C-reactive protein and a core senescence-associated secretory phenotype component	Not on standard panels; ordered specifically. Highly diurnal — drawn before 10:00 and at the same time on repeat
Tumour necrosis factor-alpha (TNF-α)	< 2.0 pg/mL	Second senescence-associated secretory phenotype component reduced by fisetin in controlled trials	Assay variability between laboratories is high; one laboratory across all timepoints
Fasting insulin	2–5 µIU/mL	Detects the metabolic effect seen in the controlled trials, earlier than glucose does	Requires 10–12 hour fast. Paired with fasting glucose to calculate insulin resistance. Conventional ranges run to roughly 25 µIU/mL, five times the functional ceiling
Fasting glucose	75–85 mg/dL	Confirms the metabolic signal and flags additive low blood sugar if on diabetes medication	Same draw as insulin. Conventional range extends to 99 mg/dL, well above the functional target
Haemoglobin A1c	< 5.4 %	Three-month average glucose; filters out day-to-day noise in fasting values	Falsely low with shortened red cell lifespan (anaemia, recent blood donation). Conventional laboratories call anything below 5.7 % normal, which sits above the functional target
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)	ALT < 20 U/L (women), < 25 U/L (men); AST similar	Liver safety; fisetin is hepatically handled and competes for conjugation pathways	Included in a comprehensive metabolic panel. Conventional upper limits near 40 U/L are population-derived and miss early change
Estimated glomerular filtration rate (eGFR)	> 90 mL/min/1.73 m²	Kidney safety; fisetin conjugates are renally cleared	Creatinine-based estimates read low in people with high muscle mass; cystatin C is the better alternative there. Conventional reporting flags only values below 60 mL/min/1.73 m², so a meaningful decline can pass unremarked
Complete blood count with platelets	Platelets 200–350 ×10⁹/L	Bleeding risk surveillance, relevant given flavonol antiplatelet activity	Most relevant for anyone on anticoagulant or antiplatelet therapy. The conventional range spans 150–450 ×10⁹/L, wide enough to hide a downward trend within it
International normalised ratio (INR)	Within the individual’s prescribed target	Detects the warfarin interaction, the fisetin interaction with the most serious potential consequence	Only applicable on warfarin. Checked within 7 days of the first cycle
Blood pressure, seated and standing	< 120/80 mmHg seated, with < 20 mmHg systolic drop on standing	Detects additive blood-pressure lowering reported with fisetin	Measured before and 2–4 hours after the dose on the first two dosing days
Lipid panel with apolipoprotein B	Apolipoprotein B < 80 mg/dL	Captures the lipid improvements seen when fisetin was combined with training	Apolipoprotein B counts atherogenic particles and is more informative than low-density lipoprotein cholesterol alone; non-fasting is acceptable. Conventional laboratories flag apolipoprotein B only above roughly 90–130 mg/dL, well above the functional target

Qualitative markers matter here more than usual, because the objective endpoint that would define success — senescent-cell burden — is not clinically measurable. Worth tracking alongside the panel:

Physical function: grip strength, chair-stand time, or gait speed, measured the same way every three months. These are the endpoints the running human frailty trials use, and they are trackable at home.
Exercise recovery: time to feel recovered after a hard session, and whether training capacity is trending up or down across cycles.
Joint stiffness and morning discomfort: the symptom domain with the clearest preclinical rationale and the one most likely to shift if anything does.
Energy and daytime fatigue: rated consistently on a simple scale, since fatigue is a primary endpoint in the cancer-survivor fisetin trials.
Cognitive clarity: subjective, unreliable in isolation, but worth recording because it is where expectation effects are strongest and where honest tracking is most likely to puncture them.
Gastrointestinal tolerance on dosing days: the most common adverse effect and the one that determines whether a protocol is sustainable.

Defining success honestly is the hard part. A reasonable standard is a measurable, sustained fall in hs-CRP and interleukin-6 beyond assay variability, plus improvement or stability in physical function, with no adverse trend in liver, kidney, or blood-pressure measures. Absent that, three to four cycles without change is a reasonable point to conclude the intervention is not doing anything detectable in that individual.

Emerging Research

Frailty and inflammation in older adults (Mayo Clinic): Two long-running phase 2 trials — NCT03675724 in older adults and NCT03430037 in older women, each with 40 participants — remain the studies most directly relevant to anyone considering fisetin for aging. Both use the intermittent high-dose protocol with frailty, inflammation, and senescent-cell markers as endpoints. Both have been running since 2018 with primary completion now listed for November 2026; their prolonged non-reporting is itself informative about how difficult these endpoints are to move or to measure.
Vascular function in older adults: NCT06133634, a phase 1/2 trial at the University of Colorado Boulder with 70 participants, tests whether fisetin improves endothelial function and arterial stiffness in older adults. It is the direct human translation of the mouse arterial work, primary completion was March 2026, and it is the single trial most likely to produce a clean positive or negative answer on a senescence-linked endpoint in healthy aging.
Mobility in peripheral artery disease: NCT06399809 at Northwestern University, a phase 2 trial in 34 participants, targets senescence and walking impairment in peripheral artery disease — a condition with high local senescent-cell burden. It is one of the few trials measuring both a senescence biomarker and a hard functional endpoint in the same participants.
Frailty in cancer survivors: NCT04733534 at St. Jude Children’s Research Hospital, with 110 adult survivors of childhood cancer, and NCT06113016, a phase 2 trial in 164 breast cancer survivors combining fisetin with exercise, both test the population with the strongest mechanistic case: people carrying a chemotherapy- and radiotherapy-induced senescent-cell burden decades early. A third trial in this population, NCT05595499 in 88 postmenopausal breast cancer survivors, has published its rationale and design (Ji et al., 2026), with six-minute walk distance as the primary endpoint.
Pharmacokinetics in young versus old adults: NCT06796374 at University Medicine Greifswald, with 80 participants, addresses the most basic unanswered question — whether older adults absorb and clear fisetin differently from younger ones. Until this reports, weight-based dosing in older adults is an assumption.
Dose-finding and safety in multimorbidity: NCT06431932, a phase 1/2 pilot in 60 healthy volunteers and older patients with multiple chronic conditions, is the first trial designed primarily to characterise fisetin’s safety and pharmacokinetics rather than to test an efficacy hypothesis. It runs to 2028 and is the study most likely to change the risk side of this review.
Acute illness: NCT05758246, a 220-participant phase 2 trial of senolytics in older adults with sepsis, is by some margin the largest senolytic trial in an acute setting and will produce the first reasonably powered safety dataset in a frail, acutely unwell population.
Evidence that could weaken the case: The strongest existing negative result is the National Institute on Aging Interventions Testing Program finding that fisetin does not extend lifespan in genetically heterogeneous mice (Harrison et al., 2024). Three further lines could weaken it more. First, the senomorphic finding that liposomal fisetin quiets the senescence-associated secretory phenotype without killing senescent cells (Henschke et al., 2025) suggests the observed anti-inflammatory effects may not require senolysis at all, undercutting the rationale for high intermittent dosing. Second, the hormesis analysis by Calabrese et al., 2025 argues fisetin’s benefits follow a biphasic dose-response, implying senolytic doses may sit past the peak. Third, the phase 2 senolytic bone trial (Farr et al., 2024) found no overall effect and benefit only in the highest-senescent-burden tertile, which if it generalises would mean most people taking fisetin have nothing to gain.
Evidence that could strengthen the case: The clearest route is a human demonstration that fisetin actually reduces senescent-cell burden in vivo, which no study has yet shown. Biomarker work is the enabling step: the characterisation of human senescent-cell biomarkers for clinical trials by Farr et al., 2025 and the identification of IL-23R (interleukin-23 receptor, a cell-surface protein whose circulating levels track senescent-cell burden) as a blood and tissue biomarker of aging (Carver et al., 2025) provide measurable endpoints that earlier trials lacked. Mechanistic work identifying CXCL12 as a mediator of fisetin’s arterial effects (Mahoney et al., 2026) offers a specific, testable causal chain rather than a general anti-inflammatory story.
Formulation as the decisive variable: The twenty-seven-fold exposure difference between formulations (Krishnakumar et al., 2022) means that trials using unformulated powder and trials using enhanced formulations are effectively testing different doses under the same name. Until trials standardise on a characterised formulation, negative results will remain ambiguous between “fisetin does not work” and “not enough fisetin arrived”. That study was funded by the formulation manufacturer and co-authored by employees of a supplement retailer, so its magnitude estimate warrants independent replication.

Conclusion

Fisetin is a cheap plant compound sold as a supplement and taken in short high-dose bursts, in the hope of clearing worn-out cells that build up with age and inflame the tissue around them. The laboratory case is genuinely strong: in cells and aged animals fisetin removes those cells selectively in some tissues, quiets inflammation, and improves several measures of function. The human case is much thinner. Small controlled trials in people with cancer, stroke, and obesity agree that fisetin lowers blood markers of inflammation, but none measured worn-out cells directly. A large independent animal programme testing survival found no benefit, which sits awkwardly beside the widely repeated result it was meant to confirm.

Safety looks good so far, with no serious harm reported at the doses studied, though the large doses reliably upset the gut, and it competes with several prescription medicines for the same route out of the body, which matters most for anyone taking blood thinners. Every published trial has been small and short, absorption from ordinary powder is poor and erratic, and product quality varies widely. Much of the enthusiastic literature comes from groups that sell fisetin, hold patents on this class of compound, or profit from the tests used to judge it, and its low cost leaves little commercial reason behind large, long studies, so the evidence is likely to stay thin. A compound that has caused few problems, with an unusually clear biological rationale and an unusually empty human record, is the honest summary.

Top - Benefits - Risks - Protocol

Fisetin as a Senolytic Therapy

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Reduction of Circulating Inflammatory Markers

Medium 🟩 🟩

Improved Outcomes When Added to Clot-Dissolving Therapy in Acute Ischemic Stroke

Improved Glucose, Insulin, and Lipid Measures Alongside Exercise

Low 🟩

Selective Clearance of Senescent Cells in Human Tissue

Preserved Physical Function and Reduced Frailty

Joint and Cartilage Protection

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

Preservation of Blood Vessel Function

Neuroprotection and Cognitive Preservation

Chemopreventive and Antitumour Activity

Protection of Kidney Function

Protection of Liver Function

Reduction in Biological-Age Measures ⚠️ Conflicted

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Absence of Long-Term Human Safety Data

Medium 🟥 🟥

Gastrointestinal Intolerance at Senolytic Doses

Interference with Drug Metabolism and Transport

Low 🟥

Genotoxicity at Supraphysiological Concentrations

Additive Blood-Pressure Lowering

Additive Bleeding Risk

Possible Interference with Chemotherapy and Radiotherapy

Speculative 🟨

Impaired Tissue Repair and Wound Healing ⚠️ Conflicted

Effects of Clearing Senescent Immune Cells

Weak Hormonal Activity

Hypersensitivity to Botanically Sourced Material

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion